Aficamten (Myqorzo) for Obstructive Hypertrophic Cardiomyopathy
The Medical Letter on Drugs and Therapeutics · 25.05.2026 · 68 (1755) · 85-87
DOI: 10.58347/tml.2026.1755c ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 25.05.2026.
Abstract (Originalsprache)
Aficamten (Myqorzo – Cytokinetics), an oral cardiac myosin inhibitor, has been approved by the FDA to improve functional capacity and symptoms in adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). It is the second cardiac myosin inhibitor to be approved in the US for this indication; mavacamten (Camzyos) was approved in 2022.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). Aficamten (Myqorzo) for Obstructive Hypertrophic Cardiomyopathy. The Medical Letter on Drugs and Therapeutics, 68(1755), 85-87. https://doi.org/10.58347/tml.2026.1755c
Vancouver
Aficamten (Myqorzo) for Obstructive Hypertrophic Cardiomyopathy. The Medical Letter on Drugs and Therapeutics. 2026;68(1755):85-87. doi:10.58347/tml.2026.1755c
BibTeX
@article{euvimed2026,
title = {Aficamten (Myqorzo) for Obstructive Hypertrophic Cardiomyopathy},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1755},
pages = {85--87},
doi = {10.58347/tml.2026.1755c}
}
EUVIMED